Proprotein Convertase Subtilisin/Kexin Type 9 Interacts With Apolipoprotein B and Prevents Its Intracellular Degradation, Irrespective of the Low-Density Lipoprotein Receptor | Zendy

Hua Sun | Zendy; Amin Samarghandi | Zendy; Ningyan Zhang | Zendy; Zemin Yao | Zendy; Momiao Xiong | Zendy; Ba-Bie Teng | Zendy

Open Access

Proprotein Convertase Subtilisin/Kexin Type 9 Interacts With Apolipoprotein B and Prevents Its Intracellular Degradation, Irrespective of the Low-Density Lipoprotein Receptor

Author(s) -

Hua Sun,

Amin Samarghandi,

Ningyan Zhang,

Zemin Yao,

Momiao Xiong,

Ba-Bie Teng

Publication year - 2012

Publication title -

arteriosclerosis thrombosis and vascular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.007

H-Index - 270

eISSN - 1524-4636

pISSN - 1079-5642

DOI - 10.1161/atvbaha.112.250043

Subject(s) - pcsk9 , kexin , apolipoprotein b , ldl receptor , proprotein convertase , endocrinology , medicine , lipoprotein , chemistry , cholesterol , low density lipoprotein , biology

proprotein convertase subtilisin/kexin type 9 (PCSK9) negatively regulates the low-density lipoprotein (LDL) receptor (LDLR) in hepatocytes and therefore plays an important role in controlling circulating levels of LDL-cholesterol. To date, the relationship between PCSK9 and metabolism of apolipoprotein B (apoB), the structural protein of LDL, has been controversial and remains to be clarified.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research